Alcidion Group's NHS contract wins fuel record cashflow and takeover speculation
A run of UK hospital software contract wins has turned Alcidion Group from a niche healthcare IT vendor into a company fund managers increasingly view as both a genuine growth story and a plausible acquisition target.
30 Jun 2026 · 5 min read
In short
Alcidion Group delivered record FY25 operating cash flow of $5.8 million on new contract wins of $73.8 million in total contract value, up 109% year-on-year, according to Salter Brothers and Cyan Investment Management.
The company was selected as preferred supplier for University Hospitals Sussex NHS Foundation Trust in January 2026, with total contract value expected to exceed A$35 million over a minimum seven-year term, later confirmed at $35-49 million.
Tamim Funds Management believes Alcidion's product-market fit and international growth potential make it a natural target for larger healthcare technology platforms or private equity looking to consolidate niche vertical software providers.
Alcidion Group Ltd (ASX: ALC) has built its fund manager following on a straightforward pattern repeated across 2025 and 2026: record cash generation from its existing UK and Australian hospital contracts, layered with a steady drumbeat of new contract wins that keep expanding its revenue base. Salter Brothers described the FY25 result as a genuine step change in execution, with revenue rising 10% to $40.8 million, underlying EBITDA swinging to a positive $5.1 million, an $8.5 million improvement on FY24, and operating cash flow of $5.8 million.
ALC enters FY26 with $34.0 million of contracted and renewal revenue already locked in, its strongest starting position to date... With recurring revenue compounding, record contract momentum, new market expansion, and restored profitability, ALC is positioned for continued operating leverage and cash-generative growth through FY26.
Salter Brothers, Monthly Report, September 2025
Contract wins keep compounding through the UK
The UK market has been the primary driver of new business. Cyan Investment Management reported in November 2025 that Alcidion announced a material $12.3 million contract expansion with Leidos Australia for electronic health records, shortly after posting record first-quarter FY26 revenue of $12.0 million. Tamim Funds Management added detail on the Leidos expansion, noting the initial multi-year deal signed in December 2021 had grown from about $23.3 million to $31.7 million, with the new addition bringing six-year value to roughly $44 million and potential 15-year value exceeding $100 million.
The largest contract yet
The most significant win landed in January 2026, when Alcidion was selected as preferred supplier for an Electronic Patient Record system at University Hospitals Sussex NHS Foundation Trust, a major healthcare provider operating seven hospitals and employing nearly 20,000 staff. Cyan Investment Management said the total contract value was expected to exceed A$35 million over a minimum seven-year term, making it one of the company's largest wins to date. By May 2026, Cyan reported the contract had been formally signed, worth $35-49 million over seven years including an $8.5 million upfront payment expected in FY26, alongside an ongoing recurring revenue stream.
ALC signed a 7yr, $35-$49m contract with University Hospitals Sussex... the contract is a huge win for an Australian company valued at less than $150m, particularly given the $8.5m upfront payment (expected in FY26) and ongoing recurring revenue stream.
Cyan Investment Management, Newsletter, May 2026
Takeover speculation builds alongside the growth
As the contract base has scaled, several managers have begun to frame Alcidion as a plausible acquisition target rather than purely a growth story in its own right. Tamim Funds Management argued in September 2025 that the company's strong product-market fit and international growth potential make it "a natural target for larger healthcare technology platforms or private equity looking to roll up niche vertical software providers," a view it repeated in November 2025 given the company had reached a scale of roughly $40 million in sales. Cyan Investment Management, one of the company's longer-term holders, has consistently pointed to Alcidion's modest market capitalisation of under $150 million relative to peers in the global health IT space as evidence the stock remains undervalued.
What managers are watching next
With FY26 contracted revenue standing at $43.1 million as of December 2025, up 40% on the prior corresponding period, and record Q3 cash receipts of $14.5 million reported in April 2026, the key catalysts fund managers are tracking are further large-scale UK NHS contract announcements of the kind that delivered the University Hospitals Sussex deal, and whether the company's growing scale and cash generation ultimately attracts the takeover interest several holders believe is increasingly likely.
Questions
What is Alcidion Group's largest recent contract win?
Alcidion was selected as preferred supplier for University Hospitals Sussex NHS Foundation Trust in January 2026, with the contract later confirmed at $35-49 million over a minimum seven-year term, including an $8.5 million upfront payment expected in FY26.
Why do fund managers see Alcidion as a takeover target?
Tamim Funds Management argues Alcidion's strong product-market fit and international growth potential, combined with a scale of around $40 million in sales, make it a natural target for larger healthcare technology platforms or private equity looking to consolidate niche vertical software providers.
How has Alcidion's cash generation improved?
Salter Brothers reported Alcidion delivered record FY25 operating cash flow of $5.8 million, an improvement of $12.9 million on the prior corresponding period, supported by new contract wins of $73.8 million in total contract value, up 109% year-on-year.
4 managers, 36 comments, with each manager's latest recorded position.
See ALC